161 related articles for article (PubMed ID: 28241173)
21. Siltuximab for Multicentric Castleman Disease-Letter.
Teipel R; Ordemann R; Proske U; Dietrich F; Mende M; Ehninger G; Kroschinsky F; Platzbecker U
Clin Cancer Res; 2015 Oct; 21(20):4740. PubMed ID: 26473194
[No Abstract] [Full Text] [Related]
22. Treatment of Idiopathic Castleman Disease.
van Rhee F; Greenway A; Stone K
Hematol Oncol Clin North Am; 2018 Feb; 32(1):89-106. PubMed ID: 29157622
[TBL] [Abstract][Full Text] [Related]
23. The role of interleukin 6 in the pathogenesis and therapy of Castleman disease - an immunologist's perspective.
Milota T; Střížová Z; Sobotková M; Bartůňková J
Cas Lek Cesk; 2023; 162(2-3):106-111. PubMed ID: 37474295
[TBL] [Abstract][Full Text] [Related]
24. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
25. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
26. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
27. Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma.
Ferrario A; Merli M; Basilico C; Maffioli M; Passamonti F
Expert Opin Investig Drugs; 2017 Mar; 26(3):367-373. PubMed ID: 28140696
[TBL] [Abstract][Full Text] [Related]
28. Siltuximab: first global approval.
Markham A; Patel T
Drugs; 2014 Jul; 74(10):1147-52. PubMed ID: 24958337
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma.
Suzuki K; Ogura M; Abe Y; Suzuki T; Tobinai K; Ando K; Taniwaki M; Maruyama D; Kojima M; Kuroda J; Achira M; Iizuka K
Int J Hematol; 2015 Mar; 101(3):286-94. PubMed ID: 25655379
[TBL] [Abstract][Full Text] [Related]
30. The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study.
Karkera J; Steiner H; Li W; Skradski V; Moser PL; Riethdorf S; Reddy M; Puchalski T; Safer K; Prabhakar U; Pantel K; Qi M; Culig Z
Prostate; 2011 Sep; 71(13):1455-65. PubMed ID: 21321981
[TBL] [Abstract][Full Text] [Related]
31. A Multicentric Castleman Disease Associated with Mixed Warm and Cold Antibody-Mediated AHA Responsive to Siltuximab.
Plano F; Mancuso S; Camarda GM; Butera MG; Sucato G; Alecci G; Florena AM; Perrone S; Siragusa SM
Chemotherapy; 2024; 69(1):35-39. PubMed ID: 37634492
[TBL] [Abstract][Full Text] [Related]
32. Siltuximab (CNTO 328): a promising option for human malignancies.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():3455-8. PubMed ID: 26170629
[TBL] [Abstract][Full Text] [Related]
33. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
34. Cutaneous castleman's disease responds to anti interleukin-6 treatment.
Ahmed B; Tschen JA; Cohen PR; Zaki MH; Rady PL; Tyring SK; Corringham RE; Kurzrock R
Mol Cancer Ther; 2007 Sep; 6(9):2386-90. PubMed ID: 17766835
[TBL] [Abstract][Full Text] [Related]
35. Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Pierson SK; Shenoy S; Oromendia AB; Gorzewski AM; Langan Pai RA; Nabel CS; Ruth JR; Parente SAT; Arenas DJ; Guilfoyle M; Reddy M; Weinblatt M; Shadick N; Bower M; Pria AD; Masaki Y; Katz L; Mezey J; Beineke P; Lee D; Tendler C; Kambayashi T; Fosså A; van Rhee F; Fajgenbaum DC
Blood Adv; 2021 Sep; 5(17):3445-3456. PubMed ID: 34438448
[TBL] [Abstract][Full Text] [Related]
36. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics of siltuximab: impact of disease state.
Nikanjam M; Yang J; Capparelli EV
Cancer Chemother Pharmacol; 2019 Nov; 84(5):993-1001. PubMed ID: 31482226
[TBL] [Abstract][Full Text] [Related]
38. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
39. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F; Voorhees P; Dispenzieri A; Fosså A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK; Partridge HL; Mukherjee S; Shilling D; Stone K; Greenway A; Ruth J; Lechowicz MJ; Chandrakasan S; Jayanthan R; Jaffe ES; Leitch H; Pemmaraju N; Chadburn A; Lim MS; Elenitoba-Johnson KS; Krymskaya V; Goodman A; Hoffmann C; Zinzani PL; Ferrero S; Terriou L; Sato Y; Simpson D; Wong R; Rossi JF; Nasta S; Yoshizaki K; Kurzrock R; Uldrick TS; Casper C; Oksenhendler E; Fajgenbaum DC
Blood; 2018 Nov; 132(20):2115-2124. PubMed ID: 30181172
[TBL] [Abstract][Full Text] [Related]
40. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
Fizazi K; De Bono JS; Flechon A; Heidenreich A; Voog E; Davis NB; Qi M; Bandekar R; Vermeulen JT; Cornfeld M; Hudes GR
Eur J Cancer; 2012 Jan; 48(1):85-93. PubMed ID: 22129890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
